Abstract: A powdery pharmaceutical composition comprising nicotine or a derivative thereof and starch microspheres. The starch microspheres are preferably degradable epichlorhydrin cross-linked starch microspheres. The average diameter of the microspheres is from around 1 .mu.m to around 200 .mu.m, preferably around 45 .mu.m. The invention also encompasses a method for manufacturing a powdery pharmaceutical composition comprising nicotine and starch microspheres. The invention further comprises a method of diminishing the desire of a subject to use tobacco which comprises the step of administering to the subject the above powdery pharmaceutical composition.

Abstract: The invention relates to the use of a preparation for insulation/sealing and coating purposes, comprising an apolar, non-setting fluid polymer having a glass transition temperature lower than -60.degree. C., wherein the polymer has a surface tension of less than 40 mN/m above the glass transition temperature. Preferably, the preparation contains one or more fillers having a different particle size and a different particle size distribution.

Abstract: Compositions and methods of the topical treatment of equine laminitis are disclosed. In particular, combinations of a fast acting nitric oxide (NO) donor, a sustained acting NO donor and an NSAID mixed in a lipid-based carrier are described. The application of such combinations to the affected areas, e.g., the hoofs and surrounding tissues, of an equine afflicted with laminitis provides relief from the debilitating effects of this painful, often life-threatening condition.

Abstract: The present invention is in the area of administration forms and delivery systems for drugs, vaccines and other biologically active agents. More specifically the invention is related to the preparation of suspensions of colloidal solid lipid particles (SLPs) of predominantly anisometrical shape with the lipid matrix being in a stable polymorphic modification and of suspensions of micron and submicron particles of bioactive agents (PBAs); as well as to the use of such suspensions or the lyophilizates thereof as delivery systems primarily for the parenteral administration of preferably poorly water-soluble bioactive substances, particularly drugs, and to their use in cosmetic, food and agricultural products.SLPs and PBAs are prepared by the following emulsification process:(1) A solid lipid or bioactive agent or a mixture of solid lipids or bioactive agents is melted.

Abstract: Disclosed are methods and means for facilitating injection which enable a correct penetration depth of the needle.

Abstract: The invention relates to methods that permit the rapid construction of oligosaccharides and other glycoconjugates. Methods for forming multiple glycosidic linkages in solution in a single step are disclosed. The invention takes advantage of the discovery that the relative reactivity of glycoside residues containing anomeric sulfoxides and nucleophilic functional groups can be controlled. In another aspect of the invention, the reactivity of activated anomeric sugar sulfoxides is utilized in a solid phase method for the formation of glycosidic linkages. The methods disclosed may be applied to the preparation of specific oligosaccharides and other glycoconjugates, as well as to the preparation of glycosidic libraries comprising mixtures of various oligosaccharides, including glycoconjugates, which can be screened for biological activity.

Abstract: The invention is directed to a method of reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia, by the administration of citicoline shortly after an ischemic episode and continuing daily treatment for up to about 30 days, preferably for at least about 6 weeks. The method is useful in the treatment of stroke and severe head trauma patients and maximizes the chances for a full or substantially full recovery of the patient. Combination treatment regimens are also disclosed along with compositions for use therewith.